Key Takeaways:

• Three net losses narrowed to $11 million, while EBITDA rose 10% to $8.9 million.
• Despite lower device sales, recurring Hydrafacial consumables dipped just 2.6%, sustaining steady revenue flow.
• Launches like HydraFillic Pep9 and Keravive strengthen BeautyHealth’s science-led, wellness-driven positioning.

The BeautyHealth Company, parent of the Hydrafacial brand, reported Q3 2025 net sales of $70.7 million, a 10.3% year-over-year (YoY) decline as macroeconomic pressures and softness in device sales weighed on results. However, the company’s bottom line improved notably, with net losses narrowing to $11 million, compared to $18.3 million in Q3 2024, supported by tighter operational spending and stronger margins.

While revenue contracted, the company’s adjusted EBITDA rose 10% YoY to $8.9 million, reflecting improved profitability and efficiency. Adjusted gross margin also expanded to 68%, up from 69.5% a year earlier, showing progress in operational optimization despite lower top-line results.

CEO Pedro Malha framed the quarter as one of “disciplined execution and the continued strengthening of BeautyHealth’s foundation,” as the company continued to transition certain markets to distributor-led models, including China, to better balance scale and profitability.

Q3 2025 Highlights

• Net Sales: $70.7 million (+10.3% YoY)
  • Delivery Systems Sales: $20.8 million (+24.6% YoY)—decline tied to slower global aesthetics spending and transition in China.
  • Consumables Sales: $49.8 million (+2.6% YoY)—would have grown modestly excluding distributor transition impacts.
    
    
• Net Loss: $11 million, an improvement of $7.3 million YoY.
• Adjusted EBITDA: $8.9 million (+10% YoY).
• Adjust...